Subject Area


Document Type

Original Study


Objective: This study aims to assess structural, refractive, and biometric outcomes and safety of intravitreal ranibizumab (IVR) for treatment requiring retinopathy of prematurity (ROP) 1-year post-IVR. Background: IVR has been proposed as alternative to conventional laser photocoagulation for treatment requiring ROP in different zones to achieve better structural and functional outcomes. Methods: A prospective case series conducted in in Menoufia university hospitals, Menoufia governorate, Egypt during the period from January 2021 to December 2022. Premature infants who met the eligibility criteria with type 1 pre-threshold ROP, threshold ROP and Aggressive-ROP (A-ROP) received IVR of 0.25mg (0.025 ml). Postoperatively, patients were reviewed to evaluate initial response, reactivation, and eventual structural and functional outcomes at 1-year post-IVR. Results: Thirty-two eyes of 19 infants received IVR with 90.26%, 3.125%, and 6.25% showing initial regression, persistence, and progression respectively. Reactivation occurred in 18.75% of eyes yet only one eye required retreatment. At1-year post-IVR, treatment was labelled successful in 87.5% of eyes with 78.57% showing full retinal vascularization. Mean spherical equivalent (SE) and axial length of treated patients were -0.98±1.036D and 20.75±0.57mm respectively with no significant difference in the different zones (p=0.069, and p=0.886 respectively). No eye showed high myopia (≥5D), nystagmus, strabismus, nor glaucoma. Conclusion: IVR is proven to be effective for management of treatment requiring ROP showing good structural and functional outcomes at 1-year follow up in different zones with good safety profile. Despite the high rate of reactivation, only limited number requires retreatment with final good results.